 |
International Journal for Research Trends and Innovation
International Peer Reviewed & Refereed Journals, Open Access Journal
ISSN Approved Journal No: 2456-3315 | Impact factor: 8.14 | ESTD Year: 2016
Scholarly open access journals, Peer-reviewed, and Refereed Journals, Impact factor 8.14 (Calculate by google scholar and Semantic Scholar | AI-Powered Research Tool) , Multidisciplinary, Monthly, Indexing in all major database & Metadata, Citation Generator, Digital Object Identifier(DOI)
|
Issue: December 2025
Volume 10 | Issue 12
Review Result and Publication of Paper within : 2-3 days
Click Here For more DetailsFor Authors
Forms / Download
Published Issue Details
Editorial Board
Other IMP Links
Facts & Figure
Impact Factor : 8.14
Issue per Year : 12
Volume Published : 10
Issue Published : 115
Article Submitted : 19456
Article Published : 8041
Total Authors : 21252
Total Reviewer : 769
Total Countries : 144
Indexing Partner
Licence
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
|
Published Paper Details
|
|
| Paper Title: | Oral Biologics Therapy For Inflammation Bowel Disease : A Review |
| Authors Name: | Ankita N. Jagtap , Shewta L.Dhande , Prashant S.Malpure , Khanderao R.Jadhav , Rishikesh S.Bacchav |
| Download E-Certificate: | Download |
| Author Reg. ID: |
IJRTI_185105
|
| Published Paper Id: | IJRTI2308016 |
| Published In: | Volume 8 Issue 8, August-2023 |
| DOI: | |
| Abstract: | Crohn's disease and ulcerative colitis are two types of the chronic gastrointestinal condition known as "inflammatory bowel disease." Chronic exacerbation and remission phases characterise it, which has a significant impact on quality of life. Although its cause is uncertain, an overactive immune response in the gut wall is what drives it. Overproduction of adhesion molecules and proinflammatory cytokines is a result of the activated immunological response. Monoclonal antibodies used in biological therapies are made in a lab to inhibit particular bodily proteins from producing inflammation. These biologics have fundamentally altered how inflammatory bowel disease is treated. Anti-tumor necrosis factor (TNF), anti-integrins, and anti-interleukin (IL) 12/23 are the three types of biologics. When compared to placebo, all biologics had a greater clinical response and mucosal healing. The most effective drug is infliximab, although it can produce antibodies that prevent it from working, which results in a loss of response in these cases, golimumab works well. If used as a first-line treatment, certolizumab is more efficient. Vedolizumab is effective if corticosteroid and immunomodulator therapy has failed. Biological therapy should replace steroid therapy because it includes the entire body and has serious side effects. However, further research is required before biological therapy may be used as the first line of treatment for inflammatory bowel disease. |
| Keywords: | Inflammation Bowel Disease, Infliximab, Adalimumab, Golimumab, Certolizumab, Vedolizumab, Ustekinumab |
| Cite Article: | "Oral Biologics Therapy For Inflammation Bowel Disease : A Review", International Journal of Science & Engineering Development Research (www.ijrti.org), ISSN:2455-2631, Vol.8, Issue 8, page no.103 - 111, August-2023, Available :http://www.ijrti.org/papers/IJRTI2308016.pdf |
| Downloads: | 000205077 |
| ISSN: |
2456-3315 | IMPACT FACTOR: 8.14 Calculated By Google Scholar| ESTD YEAR: 2016 An International Scholarly Open Access Journal, Peer-Reviewed, Refereed Journal Impact Factor 8.14 Calculate by Google Scholar and Semantic Scholar | AI-Powered Research Tool, Multidisciplinary, Monthly, Multilanguage Journal Indexing in All Major Database & Metadata, Citation Generator |
| Publication Details: |
Published Paper ID: IJRTI2308016
Registration ID:185105
Published In: Volume 8 Issue 8, August-2023
DOI (Digital Object Identifier):
Page No: 103 - 111 Country: -, -, India Research Area: Pharmacy Publisher : IJ Publication Published Paper URL : https://www.ijrti.org/viewpaperforall?paper=IJRTI2308016 Published Paper PDF: https://www.ijrti.org/papers/IJRTI2308016 |
| Share Article: | |
|
Click Here to Download This Article |
|
| Article Preview | |
|
|
|
Major Indexing from www.ijrti.org
| Google Scholar | ResearcherID Thomson Reuters | Mendeley : reference manager | Academia.edu |
| arXiv.org : cornell university library | Research Gate | CiteSeerX | DOAJ : Directory of Open Access Journals |
| DRJI | Index Copernicus International | Scribd | DocStoc |
ISSN Details
 |
 |
|
ISSN: 2456-3315
Impact Factor: 8.14 and ISSN APPROVED,
Journal Starting Year (ESTD) : 2016
DOI (A digital object identifier)
| Providing A digital object identifier by DOI.ONE How to Get DOI? |
Conference
Open Access License Policy
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Important Details
Join RMS/Earn 300
WhatsApp
Click Here
Click Here
Indexing Partner |
|||
| Copyright © 2025 - All Rights Reserved - IJRTI | |||